Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis

by Bewersdorf JP, Jaszczur SM, Afifi S, Zhao JC, Zeidan AM
Published 2019-12-01

A comprehensive insight into the clinicopathologic significance of miR-144-3p in hepatocellular carcinoma

by Liang HW, Ye ZH, Yin SY, Mo WJ, Wang HL, Zhao JC, Liang GM, Feng ZB, Chen G, Luo DZ
Published 2017-07-01